Relmada Therapeutics Inc
Change company Symbol lookup
Select an option...
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
CG Carlyle Group Inc
ETR Entergy Corp
SKIN Beauty Health Co
PYR Pyrogenesis Canada Inc
KHZM Madison Ave Media Inc
PEO Adams Natural Resources Fund
MF Missfresh Ltd
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), which is an N-methyl-D-aspartate (NMDA) receptor antagonist. The Company’s lead product candidate, esmethadone, is a new chemical entity (NCE) developed as a rapidly acting, oral agent for the treatment of depression, central nervous system (CNS) diseases and other potential indications. The Company’s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD).

Closing Price
$33.23
Day's Change
1.45 (4.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
33.44
Day's Low
31.50
Volume
(Light)
Volume:
381,525

10-day average volume:
571,687
381,525

Here's why Curaleaf looks past headwinds and sticks to 2022 revenue view

11:01 am ET May 11, 2022 (MarketWatch)
Print

By Steve Gelsi

Curaleaf sees traction in N.J., Ill., Fla., and looks toward growth in NY, Conn., and overseas

Curaleaf Holdings Inc. remains on track to generate up to $1.5 billion in revenue in 2022 -- up from $1.2 billion in 2021 -- despite a rockier first quarter, the executive chairman of the company told MarketWatch.

Boris Jordan said it's all about the second, third and fourth quarters because the Wakefield, Mass., cannabis company sees ample opportunities for growth in New Jersey and other states.

Curaleaf has reiterated its expected 2022 revenue range of $1.4 billion to $1.5 billion despite posting first-quarter revenue of $407.4 million, about $2.2 million short of the analyst estimate, according to FactSet. Curaleaf's loss of 3 cents a share matched the analyst estimate in its quarterly financial update on Tuesday.

"March was our best month in our history but January was one of worst," Boris Jordan said. "The market is coming back and we're seeing growth. We feel really good about the rest of the year."

As one of seven companies that began legal N.J. sales on April 21, Curaleaf has been supplying wholesale cannabis to the Garden State as well as operating its own store, with two more store openings on the way. Sales have been robust at its Bellmawr, N.J., store, which is running on track to generate about $100 million in sales.

Also Read: New Jersey takes step toward adult use cannabis sales

Curaleaf is also expecting to start booking revenue from a major new growing facility in Illinois during the second quarter, and it's grown its market share in Florida to 17% from 8% a year ago.

Cowen analyst Vivien Azer on Tuesday reiterated an outperform rating on Curaleaf and said the company's revenue number reflected industry trends.

"Despite deflationary/consumer headwinds, margins should expand sequentially from here on scaling cultivation and NJ," Azer said. "With solid momentum going into 2Q, we believe CURA is well positioned to return to sequential growth beginning in 2Q."

Analysts currently expect second-quarter revenue of $442.7 million for Curaleaf, up from $391.1 million in the year-ago quarter and ahead of the $407.4 million reported in the first quarter, according to FactSet data.

Curaleaf also promoted its president Matt Darin to the role of chief executive officer. Current CEO Joe Bayern will launch a new division at Curaleaf focused on consumer packaged goods.

Shares of Curaleaf traded flat on Wednesday. The stock is down 38.3% in 2022, compared to a 46% drop by the AdvisorShares Pure US Cannabis ETF (MSOS) .

Also Read:Ascend Wellness hikes purchase price in New York settlement with MedMen

-Steve Gelsi

	

(END) Dow Jones Newswires

May 11, 2022 11:01 ET (15:01 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.